Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-05-14Clinical Trial Update: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT [Phase 2]
Phase 2 study in poor-risk diffuse large B-cell lymphoma using total lymphoid irradiation and anti-thymocyte globulin, followed by matched a…
-
CLINICAL_TRIALS research · 2018-05-01Clinical Trial Update: Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma [Phase 4]
Clinical trial update for a Phase 4 study on treating elderly patients with Diffuse Large B-Cell Lymphoma; the trial status is currently unk…
-
CLINICAL_TRIALS trial_result · 2018-04-30Clinical Trial Update: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients [Phase 2]
Phase 2 trial evaluating a three-drug regimen (Tacrolimus, Bortezomib, and Thymoglobulin) to prevent low-toxicity graft-versus-host disease …
-
CLINICAL_TRIALS trial_result · 2018-04-27Clinical Trial Update: Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma [Phase 2]
The trial update reports termination of a Phase 2 study evaluating 90Y-DOTA-hLL2 as consolidation therapy after R-CHOP in patients with diff…
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: Safety Study of SGN-CD70A in Cancer Patients [Phase 1]
A Phase 1 safety study of SGN-CD70A in renal cell carcinoma and several lymphomas has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating pinatuzumab vedotin or polatuzumab vedotin in combination with rituximab or obinutuzumab for relapsed/refractory …
-
CLINICAL_TRIALS research · 2018-04-11Clinical Trial Update: A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
This entry describes a prospective clinical trial evaluating low-dose decitabine combined with the COP chemotherapy regimen for relapsed and…
-
CLINICAL_TRIALS research · 2018-04-10Clinical Trial Update: Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
This completed study investigates blood biomarkers in patients with diffuse large B-cell lymphoma using DNA microarray analysis.
-
CLINICAL_TRIALS withdrawal · 2018-04-09Clinical Trial Update: Durvalumab in DLBCL After Autologous Transplant [Phase 2]
A Phase 2 trial evaluating durvalumab for diffuse large B-cell lymphoma after autologous transplant has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-04-02Clinical Trial Update: RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating HS006 (RHCACD20MA) in combination with CHOP (Hi-CHOP) for previously untreated diffuse large B-cell lymphoma has …
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study of alisertib (MLN8237) in adults with aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle ce…
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine [Phase 1, Phase 2]
Phase 1/2 trial update of alisertib (MLN8237) in relapsed or refractory aggressive B-cell lymphomas treated with rituximab with or without v…
-
CLINICAL_TRIALS trial_result · 2018-03-19Clinical Trial Update: Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission [Phase 2]
Phase 2 trial of pidilizumab for stage III/IV diffuse large B-cell lymphoma following first remission was terminated; results were posted in…
-
CLINICAL_TRIALS trial_result · 2018-03-19Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas [Phase 2]
Phase 2 clinical trial update on peptide receptor radionuclide therapy with yttrium-90 DOTATOC in relapsed/refractory diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2018-03-14Clinical Trial Update: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma [Phase 2]
This Phase 2 trial evaluated bendamustine, obinutuzumab, and dexamethasone in older patients with diffuse large B-cell lymphoma. The study w…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
A Phase 2 multicenter randomized open-label trial evaluating MEDI-551 (milatuzumab) in adults with relapsed or refractory diffuse large B-ce…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/Phase 2 study from Lund University Hospital evaluated valproate in combination with Rituximab and CHOP as first-line the…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating intensified therapy with the ZBEAM chemotherapy regimen followed by autologous stem cell transplantation in patie…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years [Phase 2]
A Phase 2 trial studying Mini-ChOP plus Ofatumumab for first-line treatment of CD20-positive diffuse large B-cell lymphoma in patients over …
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma [Phase 3]
A Phase 3 trial investigating an investigational GA agent in newly diagnosed diffuse large B-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-02-13Clinical Trial Update: BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL [Phase 3]
A Phase 3 trial comparing BEAM conditioning with autologous stem cell transplant to BEAM with Zevalin in relapsed or refractory diffuse larg…
-
CLINICAL_TRIALS trial_result · 2018-01-25Clinical Trial Update: SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients [Phase 2]
Phase 2 clinical trial update of SAR3419 as a single agent in relapsed-refractory diffuse large B-cell lymphoma (DLBCL) has completed.
-
CLINICAL_TRIALS trial_result · 2018-01-25Clinical Trial Update: Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma [Phase 2]
Phase 2 trial update for chidamide in patients with relapse or refractory diffuse large B-cell lymphoma and follicular lymphoma is ongoing w…
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating abbreviated 3-cycle Rituximab plus CHOP immunochemotherapy in completely resected localized CD20+ diffuse large B-c…
-
CLINICAL_TRIALS trial_result · 2018-01-08Clinical Trial Update: Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase II trial of copanlisib in relapsed/refractory diffuse large B-cell lymphoma has completed with results posted in 2018.